Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
Rianne J HendriksMarloes M G van der LeestBas IsraëlGerjon HanninkAnglita YantiSetiastiErik B CornelChristina A Hulsbergen-van de KaaO Sjoerd KlaverJ P Michiel SedelaarWim Van CriekingeHans de JongPeter F A MuldersE David CrawfordJeroen VeltmanJack A SchalkenJelle O BarentszInge M van OortPublished in: Prostate cancer and prostatic diseases (2021)
SelectMDx test as a risk stratification tool for biopsy-naïve men avoids unnecessary biopsies in 38%, minimizes low-grade PCa detection, and misses only 10% high-grade PCa. Yet, using mpMRI in all patients had the highest net benefit, avoiding biopsy in 49% and missing 4.9% of high-risk PCa. However, if mpMRI availability is limited or expensive, using mpMRI-only in SelectMDx test positive patients is a good alternative strategy.